Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Forphenicinol
Forphenicinol enhanced antitumor effects of cyclophosphamide in a model of SCC
September 14th, 2005
Scientists claimed that forphenicinol (FPL) enhanced the antitumor effects of cyclophosphamide (CPA) in a model of squamous cell carcinoma (SCC). "We examined the interaction between FPL and CPA or ionizing radiation (IR) on the growth of murine SCC tumors SCCVII. Primary tumors were established in C3H mice by injecting SCCVII tumor cells subcutaneously into the right hind limb," scientists in the United States reported. "FPL (100 mg/kg for 8 days) and/or CPA (25 mg/kg twice) were administered by intraperitoneal injection. Tumors were irradiated to a total dose of 40 Gy (eight 5-Gy fractions). SCCVII tumor growth was inhibited by FPL (p=.054), IR...
Source: Vaccine Weekly (2005-09-14)
|
